Scarica l'app Stockscreener
13.77
1.99%
-0.28
Dopo l'orario di chiusura:
13.59
-0.18
-1.31%
Celcuity Inc Borsa (CELC) Ultime notizie
Celcuity to announce phase 3 VIKTORIA-1 trial results on Monday - Investing.com
Celcuity stock jumps ahead of pivotal breast cancer trial results - Investing.com Australia
Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer - Yahoo Finance
What analysts say about Celcuity Inc. stockDouble-digit growth - Autocar Professional
Celcuity Announces First Patient Dosed in Phase 3 - GlobeNewswire
Celcuity Inc. Stock Analysis and ForecastSuperior investment outcomes - Autocar Professional
Is Celcuity Inc. a good long term investmentFree Stock Market Real-Time Monitoring - jammulinksnews.com
What drives Celcuity Inc. stock priceSuperior stock growth - jammulinksnews.com
why celcuity inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
What makes Celcuity Inc. stock price move sharplyFree Elite Traders Group - Newser
How Celcuity Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser
Why Celcuity Inc. stock attracts strong analyst attentionProven High Yield Signals - Newser
Celcuity receives U.S. patent for gedatolisib dosing regimen - Investing.com Australia
How To Trade (CELC) - news.stocktradersdaily.com
Celcuity Soars 17.16% on New Patent for Breast Cancer Drug - AInvest
Celcuity Receives New Patent for Gedatolisib - MarketScreener
Celcuity receives U.S. patent for gedatolisib dosing regimen By Investing.com - Investing.com South Africa
Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 - The Manila Times
Celcuity, Inc. (NASDAQ:CELC) Receives $28.40 Average Target Price from Analysts - Defense World
Celcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market - MSN
Celcuity(CELC) Shares Soar 4.70% on Phase 2 Trial Success - AInvest
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention - PentictonNow
Learn to Evaluate (CELC) using the Charts - news.stocktradersdaily.com
Stifel Initiates Celcuity(CELC.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - Defense World
Celcuity Announces Promising Phase 1 Gedatolisib Results - TipRanks
Celcuity reports positive early data for gedatolisib in cancer trials By Investing.com - Investing.com UK
Celcuity reports positive early data for gedatolisib in cancer trials - Investing.com
Rhumbline Advisers Has $427,000 Stock Position in Celcuity, Inc. (NASDAQ:CELC) - Defense World
Analysts Set Celcuity Inc. (NASDAQ:CELC) Price Target at $30.80 - Defense World
Wealth Enhancement Advisory Services LLC Grows Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
Stocks in play: Roots Corp. - The Globe and Mail
(CELC) Trading Advice - news.stocktradersdaily.com
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Revista ADVFN
Cisco Powers AI-Ready Data Centers, From Hyperscale to Enterprise - The Globe and Mail
Millennium Management LLC Has $519,000 Stock Holdings in Celcuity Inc. (NASDAQ:CELC) - Defense World
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):